摘要
目的明确HER-2、Ki67和E-cad在乳腺癌不同分子分型中的表达改变,探究其临床意义。方法将该院2014年1月—2017年11月确诊的乳腺癌患者进行分子分型,各分型分别选取20例共100例浸润性乳腺癌病例,采用IHC检测HER-2、Ki67及E-cad蛋白表达。结果 HER-2乳腺癌中的阳性表达率为69.0%(69/100),三阴型HER-2表达率最低(30.0%),HER-2过表达型阳性率最高(85.0%),HER-2表达与腋窝淋巴结状态有关;Ki-67乳腺癌中的阳性表达率为73.0%(73/100),Luminal A型Ki67阳性率最低(40.0%),Luminal B(HER-2-)型阳性率最高(95.0%),且Ki67蛋白表达与患者年龄、肿瘤大小、组织学分级、腋窝淋巴结状态以及ER/PR状态均无关;E-cad在乳腺癌中的阳性表达率为74.0%(74/100),三阴型E-cad表达率最低(45.0%),HER-2过表达型阳性率最高(90.0%),E-cad同时与腋窝淋巴结状态和组织学分级显著相关。结论 HER-2、Ki67和E-cad在乳腺癌的发生、发展过程中起作用,三者的表达异常可能是乳腺癌的早期事件,联合检测在判断乳腺疾病的恶性度,从而判断预后方面有重要价值。
Objective To clarify the expression changes of HER-2,Ki67 and E-cad in different molecular types of breast cancer,and to explore its clinical significance.Methods The breast cancer patients diagnosed in our hospital from January 2014 to November 2017 were molecularly classified.A total of 100 cases of invasive breast cancer were selected from 20 cases.IHC was used to detect HER-2,Ki67 and E-cad protein expression.Results The positive expression rate of HER-2 breast cancer was 69.0%(69/100),the expression rate of triple-negative HER-2 was the lowest(30.0%),and the positive rate of HER-2 overexpression was the highest(85.0%).HER-2 expression was related to the status of axillary lymph node;the positive expression rate of Ki-67 breast cancer was 73.0%(73/100),the positive rate of Luminal A type Ki67 was the lowest(40.0%),and the positive rate of Luminal B(HER-2-)type of the highest(95.0%),and Ki67 protein expression was not associated with patient age,tumor size,histological grade,axillary lymph node status and ER/PR status;the positive expression rate of E-cad in breast cancer was 74.0%(74/100).The expression rate of E-cad was the lowest(45.0%),and the positive rate of HER-2 overexpression was the highest(90.0%).E-cad was also significantly associated with axillary lymph node status and histological grade.Conclusion HER-2,Ki67 and E-cad play a role in the occurrence and development of breast cancer.The abnormal expression of the three may be an early event of breast cancer.The combined detection can judge the malignancy of breast disease and judge the prognosis,which has important value.
作者
李莉
黄新
陈冬梅
俞艳
LI Li;HUANG Xin;CHEN Dong-mei;YU Yan(Department of Pathology,Second People's Hospital of Taizhou City,Taizhou,Jiangsu Province,225500 China)
出处
《世界复合医学》
2018年第6期1-3,共3页
World Journal of Complex Medicine
